Roxadustat FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 21, 2020.
FDA Approved: No
Generic name: roxadustat
Company: FibroGen, Inc.
Treatment for: Anemia Due to Chronic Kidney Disease
Roxadustat (FG-4592) is a first-in-class, orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in development for the treatment of anemia of chronic kidney disease (CKD).
Development timeline for roxadustat
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.